ReviewClinical & experimental metastasis2004
Roles for neuregulins in human cancer.
Review in Clinical & experimental metastasis, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 53 citations in OpenAlex.
- Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2018Trial
- Prognosis Relevance of Serum Cytokines in Pancreatic Cancer.BioMed research international · 2015Trial
- Review
- A DNA-nanoassembly-based approach to map membrane protein nanoenvironments.Nature nanotechnology · 2021Article
- Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease.Clinical science (London, England : 1979) · 2020Review
- Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity.Frontiers in cardiovascular medicine · 2020Review
- Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2018Article
- Overexpression of NRG1 promotes progression of gastric cancer by regulating the self-renewal of cancer stem cells.Journal of gastroenterology · 2015Article
- Review
- Hyperglycemia as a risk factor for cancer progression.Diabetes & metabolism journal · 2014Review
- Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-δ/β overexpression.Journal of the National Cancer Institute · 2014Article
- An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential.Circulation · 2013Article
- Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Expression of NRG1 and its receptors in human bladder cancer.British journal of cancer · 2011Article
- Cancer invasion and metastasis: interacting ecosystems.Virchows Archiv : an international journal of pathology · 2009Review
- The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12.Cancer research · 2009Article
- The ERBB3 receptor in cancer and cancer gene therapy.Cancer gene therapy · 2008Review
- Cell motility and cytoskeletal regulation in invasion and metastasis.Journal of mammary gland biology and neoplasia · 2007Review
- Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.Breast cancer research : BCR · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human epidermal growth factor (EGF) receptor (HER) family of receptor tyrosine kinases has frequently been implicated in cancer. Apart from overexpression or mutation of these receptors, also the aberrant autocrine or paracrine activation of HERs by EGF-like ligands may be important in cancer progression. Neuregulins constitute a family of EGF-like ligands that bind to HER3 or HER4, preferably forming heterodimers with the orphan receptor HER2. Mesenchymal neuregulin typically serves as a pro-survival and pro-differentiation signal for adjacent epithelia. Disruption of the balance between proliferation and differentiation, because of autocrine production by the epithelial cells, increased sensitivity to paracrine signals or disruption of the spatial organization, may lead to constitutive receptor activation, in the absence of receptor overexpression. Consequently, the analysis of ligand expression and/or activated receptors in tumor samples may broaden the group of patients that can benefit from targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.